Stookey Jodi D, Purser Jama L, Pieper Carl F, Cohen Harvey J
Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina 27710, USA.
J Am Geriatr Soc. 2004 Aug;52(8):1313-20. doi: 10.1111/j.1532-5415.2004.52361.x.
To determine whether plasma hypertonicity might be a marker of early frailty, this study tested the associations between plasma hypertonicity, incident disability, and mortality in nondisabled older adults.
Longitudinal, observational study.
Community-based.
Older adults (> or =70), who reported no disability and gave blood in the 1992 Duke Established Populations for Epidemiologic Studies of the Elderly survey (n=705), were re-interviewed in 1996 for functional status (n=561) and followed for all deaths up to January 1, 2000.
Plasma tonicity was estimated from plasma glucose, sodium, and potassium measures and used to classify subjects as normo- (285-294 mOsm/L) or hypertonic (> or =300 mOsm/L). Disability was defined as any impairment on the Rosow-Breslau, activity of daily living (ADL), and instrumental activity of daily living (IADL) scales. The relative risk (RR) of any new disability and relative hazard of death associated with hypertonicity were estimated using logistic regression models and Cox proportional hazards models, respectively. All models were controlled for age, sex, race, weight status, current smoking, activity level, plasma blood urea nitrogen and creatinine, cognitive impairment, depression, and chronic disease status. To determine whether observed effects were attributable to plasma glucose alone, all models were repeated on a subsample of nondiabetic, normoglycemic subjects.
Plasma hypertonicity (observed in 15% of subjects) was associated with increased risk of new Rosow-Breslau (RR=2.1, 95% confidence interval (CI)=1.2-3.6), IADL (RR=2.3, 95% CI=1.2-4.3), and ADL (RR=2.7 95% CI=1.3-5.6) disability by 1996 and mortality by 2000 (RR=1.4, 95% CI=1.0-1.9). Results were similar for the normoglycemic subgroup (ADL: RR=2.9, 95% CI=1.0-8.0; IADL: RR=2.5, 95% CI=1.0-6.3; Rosow-Breslau: RR=1.8, 95% CI=0.8-3.9; mortality: RR=1.5, 95% CI=0.9-2.3).
Plasma hypertonicity may be a marker of early frailty. It was prevalent in this sample of nondisabled community-dwelling older adults and predicted incident disability and mortality. Further research to identify its determinants and consequences may help inform interventions against frailty.
为了确定血浆高渗是否可能是早期衰弱的一个标志物,本研究检测了非残疾老年人血浆高渗、新发残疾和死亡率之间的关联。
纵向观察性研究。
基于社区。
年龄≥70岁、在1992年杜克老年流行病学研究既定人群调查中报告无残疾且献过血的老年人(n = 705),于1996年再次接受关于功能状态的访谈(n = 561),并对直至2000年1月1日的所有死亡情况进行随访。
根据血浆葡萄糖、钠和钾的测量值估算血浆渗透压,并用于将受试者分类为等渗(285 - 294 mOsm/L)或高渗(≥300 mOsm/L)。残疾定义为在罗索 - 布雷斯劳量表、日常生活活动(ADL)量表和工具性日常生活活动(IADL)量表上的任何损伤。分别使用逻辑回归模型和Cox比例风险模型估算与高渗相关的任何新发残疾的相对风险(RR)和死亡的相对风险。所有模型均对年龄、性别、种族、体重状况、当前吸烟情况、活动水平、血浆尿素氮和肌酐、认知障碍、抑郁和慢性病状况进行了校正。为了确定观察到的效应是否仅归因于血浆葡萄糖,在非糖尿病、血糖正常的受试者子样本上重复了所有模型。
血浆高渗(在15%的受试者中观察到)与到1996年新出现的罗索 - 布雷斯劳残疾(RR = 2.1,95%置信区间(CI)= 1.2 - 3.6)、IADL残疾(RR = 2.3,95% CI = 1.2 - 4.3)和ADL残疾(RR = 2.7,95% CI = 1.3 - 5.6)风险增加以及到2000年死亡率增加(RR = 1.4,95% CI = 1.0 - 1.9)相关。血糖正常亚组的结果相似(ADL:RR = 2.9,95% CI = 1.0 - 8.0;IADL:RR = 2.5,95% CI = 1.0 - 6.3;罗索 - 布雷斯劳:RR = 1.8,95% CI = 0.8 - 3.9;死亡率:RR = 1.5,95% CI = 0.9 - 2.3)。
血浆高渗可能是早期衰弱的一个标志物。它在这个非残疾社区居住老年人样本中很普遍,并可预测新发残疾和死亡率。进一步研究以确定其决定因素和后果可能有助于为抗衰弱干预提供信息。